Second Look Laparoscopic Surgery with Heated Chemotherapy for the Treatment of Patients with Stage I-IVA Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• Patients must have histologically I-III epithelial carcinoma of the ovary, fallopian tube or peritoneum or stage IVA disease in which there is complete resolution of disease (pleural effusion) with chemotherapy
• Patients must have undergone cytoreductive surgery and 3-8 cycles of platinum-based systemic chemotherapy prior to the second look surgery. Systemic platinum based chemotherapy must be completed <18 weeks prior to second look surgery
• Cytoreductive surgery must result in an R-0, R-1 resection prior to systemic chemotherapy
• The intraoperative peritoneal adhesion index should be =< 10
• Patients must be without clinical evidence of disease including a negative exam, imaging (computed tomography [CT] or positron emission tomography [PET/CT]) and normal tumor markers (CA125) after completion of systemic chemotherapy
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Absolute neutrophil count > 1,500/mcL (within 30 days of registration)
• Platelets > 100,000/mcL (within 30 days of registration)
• Total bilirubin =< 1.5 mg/dL (within 30 days of registration)
• Creatinine clearance >= 50 mg/dL (within 30 days of registration)
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal (within 30 days of registration)
• Alkaline phosphatase =< 3 x institutional upper limit of normal (within 30 days of registration)
• Adequate contraception and negative pregnancy test if pregnancy possible
• Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document

Exclusion Criteria

• Patients greater than 18 weeks from their last course of systemic platinum based chemotherapy
• Patients who have received additional chemotherapy for the ovarian cancer after primary therapy as outlined above
• Patients may not have received prior abdominal or pelvic radiation
• Extensive intra-abdominal adhesive disease noted at the time of initial cytoreductive surgery with peritoneal adhesion index (PAI) of > 10 as defined above
• Intra-abdominal infection associated with initial cytoreductive surgery requiring extended hospitalization or related to systemic chemotherapy requiring hospitalization for therapy
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnancy
• Men are excluded from participation due to the site-specific nature of the disease being studied